Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

How Has The Zolgensma Market Size Shifted, And What Is the Outlook Through 2034?

The market size of Zolgensma grew at a rate of XX (HCAGR) in the last few years. The prediction is that it would increase from $XX million in 2024 to $XX million in 2025, showcasing a compound annual growth rate (CAGR) of XX%. The historic period growth is linked to the growing incidence of spinal muscular atrophy, increased cognizance of genetic disorders, heightened health care expenditure, the prevalence of genetic testing, and the growing number of health insurance policies.

In the coming years, the zolgensma market size is forecasted to observe a XX (FCAGR). By 2029, it is expected to reach a value of $XX million, with a compound annual growth rate (CAGR) of XX%. The rising inclination towards personal medicine methods, surge in worldwide healthcare expenditure, expansion in telemedicine, growing focus on treating rare diseases, and progresses in digital health technologies all contribute to the projected growth in this period. Major trends expected in this period include advancements in gene therapy technologies, improved manufacturing processes, the emergence of new biomarkers, progresses in digital health technologies, and the creation of intrathecal formulations.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20373&type=smp

Which Primay Drivers Are Accelerating Growth in the Zolgensma Market?

The zolgensma market is expected to be propelled forward by the rising occurrence of spinal muscular atrophy. This genetic disorder, mainly affecting infants and young children, is characterized by the deterioration of motor neurons in the spinal cord, leading to progressive muscle decline and atrophy and potential severe physical disabilities and life-threatening complications. The uptick in spinal muscular atrophy cases is largely due to advancements in genetic testing and newborn screening programs, allowing earlier and more precise diagnoses, thus identifying previously unrecognised cases. By providing a functional copy of the SMN1 gene to those with the disease, Zolgensma addresses its core genetic cause and aids in the restoration of the survival motor neuron protein, which is instrumental for motor operation and muscle strength. This ultimately improves motor abilities and survival chances in affected infants and children. For instance, National Health Service England, a UK government agency, reported in August 2023 that around 70 children are born with spinal muscular atrophy every year in the UK. By November 2022, 118 of 161 patients with Type 1 SMA were living beyond the age of two without the necessity for constant ventilatory support. Hence, the growing occurrence of spinal muscular atrophy fuels the expansion of the zolgensma market.

Which Primary Segments of the Zolgensma Market Are Driving Growth and Industry Transformations?

The zolgensma market covered in this report is segmented –

1) By Indication: Spinal Muscular Atrophy (SMA) Type 1; Spinal Muscular Atrophy (SMA) Type 2; Spinal Muscular Atrophy (SMA) Type 3; Pre-symptomatic Spinal Muscular Atrophy (SMA)

2) By Age Group: Pediatric (Infants And Children); Adults

3) By Distribution Channel: Hospitals; Specialty Clinics; Pharmacies

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=20373&type=smp

Which Regions Are Key Players in the Growth of the Zolgensma Market?

North America was the largest region in the zolgensma market in 2024. The regions covered in the zolgensma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Technological Trends Are Reshaping the Zolgensma Industry Dynamics?

The prevailing trend in the zolgensma market involves strategic investments with the purpose of enhancing production capacity, broadening geographical scope, and speeding up research and development activities for novel gene therapy solutions. Such investments aid in boosting production capacity to meet the growing demand, foster R&D for advancing gene therapy, facilitate the extension of geographical presence to cater more patients worldwide, make supply chains more efficient and promote partnerships to increase awareness and access to treatments. To exemplify, in April 2022, Novartis AG, a pharmaceutical corporation based in Switzerland, procured commercial licensure approval from the US Food and Drug Administration for its gene therapy manufacturing facility located in Durham, North Carolina. This approval facilitates the 170,000-square-foot facility to create, inspect, and market commercial Zolgensma and produce gene therapy products for ongoing and prospective clinical trials. The facility will also aid the manufacturing of gene therapy products for existing and up-and-coming clinical trials.

View the full report here:

https://www.thebusinessresearchcompany.com/report/zolgensma-global-market-report

What Parameters Are Used to Define the Zolgensma Market?

Zolgensma refers to a gene therapy developed to treat spinal muscular atrophy (SMA), a rare genetic disorder that leads to muscle weakness and motor function loss. It is used for replacing the defective or missing SMN1 gene in children under the age of two, helping to restore motor function and improve survival outcomes.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20373

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model